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Abstract—Large-scale studies estimate the heritability of blood pressure at 50%. We carried out a genome-wide linkage
analysis to search for chromosomal loci that might explain this heritability using longitudinal, multiple measures of
systolic and diastolic blood pressure obtained in sibling pairs and dizygotic twin pairs from 2 countries (a total of 286
pairs from Australia and 636 pairs from the Netherlands). These pairs and a large number of their parents were
genotyped with microsatellite markers. Multivariate linkage analysis of the combined data of both countries, using a
variance components approach, showed suggestive linkage for diastolic blood pressure on chromosomes 5p13.1
(logarithm of odds score: 2.48), 14q12 (logarithm of odds score: 2.40) and 17q24.3 (logarithm of odds score: 2.36). The
highest logarithm of odds score of 1.21 for systolic blood pressure was observed on chromosome 13q34. These results
replicate earlier findings and add to a slowly emerging picture of multiple loci contributing to quantitative blood pressure
variation. (Hypertension. 2007;49:832-838.)
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Hypertension is a common and complex disorder thataffects 31.0% of people 45 years of age and 77.6% of
subjects 75 years,1 thereby substantially increasing their
risk for cardiovascular disorders, notably ischemic heart
failure and stroke.2 Numerous studies have shown that
genetic factors play a role in hypertension, as well as in the
underlying quantitative trait, blood pressure (BP).3 The her-
itability for both systolic BP (SBP) and diastolic BP (DBP) is
50% and is remarkably stable over populations and time,
but the identification of quantitative trait loci (QTL) influ-
encing BP and hypertension is a complex endeavor.4–8 Many
genome scans have been performed, but most of the reported
BP loci are not yet robustly replicated, and larger studies and
meta-analyses of data tend to show less significant results.7,8
Reasons for these findings may include a large number of
genes with small effects involved, which are difficult to
detect; true heterogeneity between populations; the some-
times relatively small sample sizes; different designs and
analytical approaches; different definitions of the phenotype
(hypertension or quantitative BP scores); different treatment
of subjects who take antihypertensive medication; and the use
of different covariates.
In 2 recent studies from the Netherlands Twin Register and
the Australian Twin Register, we found that the genetic
variance in longitudinal BP data is largely attributable to
stable genetic factors.6,9 Simulations have shown that the use
of such longitudinal data sets increases the power to detect
QTLs.10 We carried out a scan on repeated measures of BP
over a 7- to 12-year period to localize genes that may explain
BP heritability.
Methods
Subjects
Longitudinal BP data for 3472 monozygotic (MZ) twins, dizygotic
(DZ) twins, and siblings were collected from 7 studies that were
performed in the Australian Twin Register (n3) and Netherlands
Twin Register (n4).11–19 BP data from all of the possible quasi-
independent sibling pairs with 1 measure in both siblings were
used for linkage analysis (MZ twin pairs with an additional sibling
counted once). The average time between the longitudinal measures
was 12 years in Australia and 7 years in the Netherlands. Subjects
were recruited on a voluntary basis from the general population.11–19
Recruitment of subjects for the first Australian study was based on
word of mouth, media appeals, and advertising.15 The second and
third studies were a follow-up of this sample, where in the third
study, subjects were added who joined the Australian Twin Register
during various (telephone) surveys of other studies.16,17 For the
Netherlands, recruitment for the first study was through city council
population registries. Subjects for the other studies were recruited
through city council population registries, advertisements in twin
newsletters, and other media.11,14 In consecutive Netherlands Twin
Register studies, earlier participating twins might participate, and
new subjects were added. The studies were approved by the
appropriate ethics committees, and informed consent was obtained
from all of the participants.
Measures
BP during rest was obtained using slightly different methods and
included manual readings by a nurse,15 brachial cuff measurements
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with an automated Dynamap 845 recorder,11,12,14,16,17 and assessment
with an ambulatory monitor (Spacelabs 90207).13 A mean of 2 to 6
BP measures was taken as the resting value. In the Dutch ambulatory
BP study, the mean (3.8) of all evening measures when subjects were
seated quietly was used. If subjects took antihypertensive medica-
tion, a correction of 14 mm Hg for SBP and 10 mm Hg for DBP
was made for the nonambulatory studies.6,20,21 For the ambulatory
study, the correction was drug class specific, and mean values were
close to 14 mm Hg for SBP and 10 mm Hg for DBP.13
Genotyping
DNA was extracted from either whole blood or buccal swaps using
standard protocols.22,23 Samples were genotyped by the Mammalian
Genotyping Service in Marshfield, the Molecular Epidemiology
Section, Leiden University Medical Centre, Sequana, or Gemini
(Australian samples).24 The genotype data from these screens were
combined but were kept separate for each country. Pedigree relations
were checked with Graphic Representation of Relationships.25 Errors
of Mendelian inheritance were detected with Pedstats.26 Markers and
samples were removed if their total error rate was 1%; in all of the
other cases, the specific erroneous genotypes were set as unknown.
Unlikely recombinants were detected using Merlin, and erroneous
genotypes were removed with Pedwipe.26 Sibling pairs were selected
that had 200 autosomal markers genotyped for each individual.
This resulted in a sample of 286 pairs for Australia. On average, 807
markers were tested per sibling (206 to 1648) with an average
heterozygosity of 76% and an average centimorgan spacing of 5.6.
For the Netherlands, 636 pairs were available. In the Dutch families,
544 parents were genotyped. Their information was used to obtain
estimates of identity-by-descent (IBD) status in the offspring. The
average number of markers genotyped in siblings was 383 (range:
201 to 743), and the average heterozygosity of autosomal markers
was 76% with an average spacing of 9.7 cM. For the statistical
analyses, the Haldane mapping function was used; all of the reported
values are in Kosambi centimorgans. Marker positions were inter-
polated via locally weighted linear regression from National Center
for Biotechnology Information build 35.1 physical map positions and
the Rutgers genetic map.27,28 Data from 648 MZ pairs were included
to estimate the contribution of background heritability.
Statistical Analysis
We estimated the probabilities that 0, 1, or 2 alleles are shared IBD
for each sibling pair using a 2 cM spacing multipoint scan with
Merlin.26 When parents were genotyped, their information was used.
When parents were not genotyped, IBD was estimated using popu-
lation marker allele frequencies that were obtained from the observed
genotype data from each country.
Multivariate linkage analysis was carried out using structural
equation modeling as implemented in the program MX using the data
of all of the possible sibling pairs.29 The multivariate structure
consisted of the 3 or 4 longitudinal measurements in Australian and
Dutch studies, respectively. Data from the 2 countries were first
analyzed separately and next combined. The total variance of BP was
partitioned into the sources of variation because of additive genetic
components (A), nonshared environmental influences (E), and the
variance explained by a putative QTL (Q). The QTL was modeled as
a single latent factor that explained an equal amount of variance in
all of the measurements, that is, the factor loadings were constrained
to be equal over time. Modeling the QTL in such a way focuses the
linkage analysis on genes that influence BP across age. The local-
ization of age-specific QTLs was not modeled, because our previous
studies showed that such QTLs did not appear to be present.6,9
To accommodate any residual unique environmental and genetic
(co)variance, A and E were modeled using a full triangular decom-
position.6,9 For DZ twin and sibling pairs, the covariance between
sibling pairs was modeled as: 0.5A  ˆijk Q, where ijk equals the
proportion of alleles shared IBD between siblings j and k for the i-th
family. For MZ twins, the covariance was modeled as A  Q,
because they share their full genome. The model for the means
included a linear regression of age and sex for each study (allowing
for study heterogeneity between measurements) and was modeled
simultaneously with the ANOVA components. Significance of the
genetic variation because of a QTL was evaluated by likelihood ratio
tests comparing the model with the Q variance component to the
model without. The resulting 2 difference was divided by 2ln10
(4.6) to obtain the logarithm of odds (LOD) score. Nominal
1-sided P values were calculated using a 50:50 20,1 distribution, a
50:50 mixture of a 20 distribution with a point mass of 0, and a 21
distribution. Accordingly, a significance level of  was obtained
from a 21 critical value of 2.
In the joint analysis, heterogeneity and homogeneity of the QTL
effect between the 2 countries was considered. Under heterogeneity,
all of the model parameters (A, E, and Q) between countries were
freely estimated. Using a likelihood-ratio test (21), we first tested
the assumption of homogeneity in the variance associated to a
putative QTL by restricting Q to be the same across both countries
while allowing other parameters to differ.30 If homogeneity of Q is
observed (P0.05), a combined linkage analysis can be used next to
determine the significance of the QTL effect on the basis of the
pooled data set using the 20,1 distribution without an increased
threshold for significance (because there is no extra free parameter
because of heterogeneity). Therefore, we report replicated loci with
LOD scores1.18 (P0.01), as well as new loci with an LOD2.2
(P0.00074), the asymptotic threshold for suggestive linkage as
suggested by Lander and Kruglyak.31 The 1-LOD drop support
interval was used as an estimate for the 90% CI of any QTL
location32 and was used to examine linkage replication compared with
previously reported locations and candidate genes (using Ensembl:
http://www.Ensembl.org and OMIM: http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?dbOMIM).
Results
The number of individuals, number of subjects using antihy-
pertensive medication, male–female ratio, average age, and
average BP levels are shown in Table 1. No differences in BP
levels were found between MZ and DZ twins and siblings. In
the later studies, an increase in age range and BP variance is
seen (study 3 from Australia and studies 3 and 4 from the
Netherlands). Between the 2 countries, the age range is
comparable. Age and sex differences were described previ-
ously in detail.6,9 Briefly, SBP levels in men were5 mm Hg
higher than in women. DBP levels in men were generally
3 mm Hg higher than in women. Increasing BP with
increasing age was seen in all of the studies, but the age effect
did not always reach significance (P0.01). There were no
sex differences in MZ correlations or DZ same-sex versus
opposite-sex correlations (P0.01), suggesting that the same
genes influence BP in men and women.
In Figure 1, the linkage results of the country-specific
genome scans are presented for SBP. The best LOD scores of
1.67 (P0.0028) and 1.27 (P0.0078) for SBP were found at
chromosome locations 5q35.1 and 11q24.2 in Australia. For
the Netherlands, the highest LOD score, 1.21 (P0.0092),
was found on chromosome 13q34 for SBP. Figure 2 shows
the linkage analyses for DBP. In the Netherlands Twin
Register sample, suggestive linkage was obtained for chro-
mosome 5p13.1 with an LOD score of 2.50 (P0.00034). In
the Australian Twin Register, this location was not replicated,
however. At a lower pointwise significance level for replica-
tion (LOD 1.18; P0.01), both SBP and DBP showed a
signal at 5q35.1 and 11q24.2. Locations showing increased
IBD sharing for either DBP or SBP were at 3p14.1, 5p13.1,
5q35.1, 7p21.3, 7q21.13, 9q33.1 to 34.2, 10p12.31, 11q13.4
to 11q24.2, 13q34, 14q12, 17p12, 17q24.3, and 19p13.3.
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Table 2 summarizes the results of the joint genome scan.
By combining the data of the 2 countries in a single scan, 3
locations with suggestive linkage were identified for DBP,
which would not have been detected using the data in the
individual countries alone. No significant heterogeneity was
found for these locations, with P values of 0.56, 0.93, and
0.47, respectively. The 3 loci were 5p13.1 at marker
ATAG022, 14q12 at marker GATA43H01, and 17p12 at
marker D17S921, with maximum LOD scores of 2.48
(P0.00037), 2.40 (P0.00045), and 2.36 (P0.00049),
respectively. For SBP, no locations with suggestive linkage
were identified. Locations for the joint scan with nominal
Ps0.01 for either SBP or DBP, which were identified
previously in other studies, are also shown in Table 2. For the
locations on chromosomes 5p13.1, 14q12, and 17p12, more
details are depicted in Figure 3.
Discussion
This study presents suggestive linkage for DBP on 3 loca-
tions, namely, 5p13.1, 14q12, and 17p12. For SBP, no
suggestive evidence for linkage was found. Several locations,
found previously in 1 study, have been replicated to some
TABLE 1. Characteristics of Studied Individuals With Genotype and Phenotype Data
Country Group Variable Study 1 Study 2 Study 3 Study 4*
Australia MZ N 176 (2) 110 (1) 638 (60)
Male/female 86/90 48/62 188/450
Age 24.3 (5.3) 34.2 (5.0) 45.7 (11.9)
SBP 114.4 (13.8) 119.3 (14.4) 128.7 (17.7)
DBP 71.0 (11.8) 73.3 (11.0) 77.9 (11.9)
DZ N 212 (3) 142 (1) 455 (38)
Male/female 93/119 61/81 170/285
Age 22.3 (4.3) 33.6 (4.6) 43.0 (11.0)
SBP 113.4 (13.6) 120.1 (11.8) 127.3 (16.8)
DBP 71.0 (11.0) 73.6 (9.2) 77.6 (11.5)
Netherlands MZ N 140 (0) 190 (10) 261 (10) 148 (7)
Male/female 70/70 92/98 117/144 53/95
Age 16.3 (2.0) 44.2 (6.7) 38.1 (12.8) 30.6 (11.5)
SBP 117.4 (7.5) 125.1 (12.9) 125.8 (14.8) 126.4 (11.4)
DBP 66.6 (5.7) 77.2 (10.6) 76.1 (11.3) 77.6 (9.2)
DZ and siblings N 164 (0) 212 (16) 313 (21) 364 (11)
Male/female 80/84 102/110 130/183 146/218
Age 17.1 (2.0) 44.1 (6.6) 36.8 (12.9) 32.9 (11.8)
SBP 117.5 (8.0) 126.3 (14.2) 126.6 (15.1) 126.1 (11.6)
DBP 66.9 (6.7) 77.0 (10.3) 77.3 (10.9) 77.3 (9.1)
N indicates the total number of individuals in each study, in brackets the number of persons using medication. Age indicates age
at time of measurement.
*This study measured BP with an ambulatory device during quiet sitting in the evening.
Figure 1. Multipoint linkage results for SBP in Australia and the Netherlands. On the horizontal axis, the chromosome number is indi-
cated. The vertical axis indicates the LOD score.
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extent (LOD: 1.18; P0.01) in our study, namely, 3p14.1,
5p13.1, 5q35.1, 7p21.3, 7q21.13, 9q33.1 to 34.2, 10p12.31,
11q13.4 to 11q24.2, 13q34, 14q12, 17p12, 17q24.3, and
19p13.3.8,33–40 However, the significance of the loci in the
individual studies is often low, the regions are broad, and the
significance tends to go down when the sample size is
increased.7,8 This pattern of findings can be caused by several
factors, but it is likely that many genes contribute to BP
variance and that each has only a small effect. With current
study sample sizes, locations of these genes may be missed.31,40
To increase power, several approaches can be used, such as
pooling across samples and the use of repeated measures in a
longitudinal design, as was done in the present study.
Medication use may affect QTL detection, but is unlikely
to have been very important here. The average age at time of
participation in most studies is still relatively low for frequent
use of antihypertensive medication. Roughly 4% of the
subjects were using antihypertensive medication. These sub-
jects were not excluded, because previous studies have shown
that excluding medicated hypertensive persons from the
analysis reduces the genetic effect and power to detect
QTLs.20,21,41 Instead, we added the published treatment ef-
fects of their medication to the observed BP. When we
examined which sibling pairs were responsible for the in-
creased LOD scores at putative locations, a general finding
was that concordant low BP pairs contributed most and not
the pairs with high BP (data not shown). Note that this finding
may be important for replication in studies examining only
hypertensive pairs. Also, it indicates that there was probably
a small influence of genes related to secondary forms of
hypertension (caused by, eg, renal disorders or type 2
diabetes), which has not been excluded in this study.
Many candidate genes are located within the 90% CI of the
3 suggestive loci at 5p13.1, 14q12, and 17p. For the 5p13.1
location, a candidate gene is the atrial natriuretic peptide
clearance receptor precursor gene (NPR3). The natriuretic
peptides elicit a number of vascular, renal, and endocrine
effects that are important in the maintenance of BP.42 The
NPR3 gene has already been associated with familial hyper-
tension, but conformation is still needed.43 Two other candi-
dates in the 5p13.1 region are the insulin gene enhancer
protein gene (ISL1) and the lipid phosphate phosphohydro-
Figure 2. Multipoint linkage results for DBP in Australia and the Netherlands. On the horizontal axis, the chromosome number is indi-
cated. The vertical axis indicates the LOD score.
TABLE 2. Genome-Wide Scan Locations With Ps<0.01 from the Joint Linkage Analysis of the
Australian and Netherlands Longitudinal Blood Pressure Studies
BP Chromosome Position, cM Marker
No Heterogeneity
P
Homogeneity Model
LOD P
DBP 3p14.1 88.2 D3S1285 0.40 1.60 0.0033
DBP 5p13.1 60.8 ATAG022 0.56 2.48 0.00037
DBP 9q33.1 121.6 D9S1776 0.36 1.54 0.0039
DBP 9q34.2 154.9 CTAT016 0.20 1.59 0.0034
DBP 11q13.4 84.3 D11S2371 0.41 1.73 0.0024
SBP 13q34 113.7 D13S1315 0.67 1.21 0.0091
DBP 14q12 19.6 GATA43H01 0.93 2.40 0.00045
DBP 17p12 43.1 D17S921 0.47 2.36 0.00049
DBP 17q24.3 109.8 GATA63G01 0.66 1.24 0.0083
Heterogeneity testing: P value for the test of the assumption that there is no heterogeneity of the QTL effect
between the 2 countries. Linkage under the homogeneity model: QTL analysis under the assumption that an equal
amount of variance is explained by the QTL in the 2 countries. Positions in Kosambi centimorgans.27
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lase 1 gene (PPAP2A). Insulin metabolism, lipid metabolism,
and BP regulation are strongly intertwined, and detrimental
shifts in these risk factors for cardiovascular disorder often
co-occur (the metabolic syndrome), possibly because of a
joint genetic underpinning.44–46
For the second region on chromosome 14q12, 2 candidate
genes were found, namely the low-density lipoprotein receptor–
related protein 10 precursor gene (LRP10) and the chymase
precursor gene (CMA1). The second is related to the angio-
tensin pathway and causes hypertension and arteriopathy in
rats when the gene is upregulated.47 However, in a large study
with Japanese subjects, variations in this gene did not show
any association with BP.48
For the third region, 17p12, the 90% CI is substantial.
Several studies have indicated that there is probably 1 gene
regulating BP on chromosome 17.49 Because BP depends on
salt balance, allelic variants of genes that influence this
balance can be considered as potential candidates. In the
17p12 region, there are several of those genes, namely the NO
synthase IIB and IIC genes (NOS2A and NOS2B), the solute
carrier family 13-member 2 renal sodium/dicarboxylate co-
transporter gene (SLC13A12), the solute carrier family 5
sodium/glucose cotransporter member 10 gene (SLC5A10),
and the ATP-sensitive inward rectifier potassium channel 12
gene (KCNJ12).49–51 Other candidates are genes involved in
syndromes caused by more severe DNA alterations; 2 located
near 17p12 are neurofibromatosis (NF1 gene) causing renal
vascular damage52,53 and platelet glycoprotein IV deficiency
(CD36 gene) leading to a changes in all of the factors
involved in the metabolic syndrome.54,55 Another candidate
involved in lipid metabolism within the 17p12 region is the
fatty aldehyde dehydrogenase gene (ALDH3A2). Further-
more, at each candidate location, genes related to the ubiq-
uitin–protein ligase family were present. Ubiquitin has been
linked to angiotensin II pathways and Na channel function
in endothelial cells.56–58 These genes could, therefore, be
considered potential candidates as well.
Perspectives
In this study, we found suggestive linkage for DBP at 5p13.1,
14q12, and 17p12. These loci have been replicated, and our
study indicates further evidence for their involvement. Fine
mapping of these regions, preferably by dense coverage of
single nucleotide polymorphism markers, followed by fam-
ily based association studies, is now a first priority. Next,
functional variants that predispose to hypertension or a
lower BP instead can be identified, as well as the pathways
involved.
Figure 3. Detailed maps of the chromosomes with suggestive linkage for DBP. On the horizontal axis, the position on the chromosome
is indicated in Kosambi centimorgans. On the vertical axis, the LOD score is given. The vertical dotted lines indicate the 90% CI
around the maximum LOD score. On top, the tested markers are presented and in the right corner the chromosome band.
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